After a $197M BARDA Deal for NexoBrid, MediWound Just Got Europe's Attention (NASDAQ: MDWD)

When the European Union created the Health Emergency Preparedness and Response Authority (HERA) in the wake of COVID-19, the goal was not just to react to the next crisis but to get ahead of it. HERA was built from the ground up with a broad mandate and serious funding behind it: threat identification, countermeasure development, crisis-phase coordination across 27 member states, and manufacturing and stockpiling oversight. Think of it as Europe's answer to a combined BARDA, the U.S. agency that funds and procures medical countermeasures, and FEMA, with added strategic procurement authority.

Within HERA sits the Joint Industrial Cooperation Forum, or ICF, a formal body that brings together EU member states and a select group of industry participants to identify supply chain vulnerabilities, manufacturing bottlenecks, and market failures that could limit countermeasure availability. In 2024 the forum included 20 participants across industry and government, reflecting its importance as a coordination hub for preparedness strategy.

Membership is limited to organizations whose capabilities align with Europe's most critical preparedness needs, and the ICF plays a direct role in shaping which technologies get prioritized and how industrial capacity aligns with those priorities. HERA backs its priorities with real capital, having deployed billions in funding for countermeasure development, joint procurement, and industrial capacity building since its creation.

The Company It Keeps

The caliber of participants underscores this point. BioNTech (NASDAQ: BNTX), which rocketed to global prominence after co-developing one of the first COVID-19 vaccines, is an ICF member. So is Fabentech, a French biopharmaceutical company that received the first-ever HERA Invest agreement, a EUR 20 million commitment to develop broad-spectrum therapeutics against high-priority biological threats. These are not typical commercial pharma companies. They are organizations that governments turn to when preparing for the next health emergency.

Against that backdrop, MediWound's recent inclusion in the ICF, which now has 64 industry members, is strategically notable. The company's lead product, NexoBrid, is already approved in Europe, the United States, Japan, and over 40 countries for enzymatic burn debridement. NexoBrid selectively removes dead tissue in severe burns in a single topical application, without surgery, preserving viable tissue underneath. That capability alone differentiates it from most wound care products. But what makes it a preparedness asset, rather than just a clinical tool, is what happens in the kinds of scenarios HERA was built for.

Why NexoBrid Is a Preparedness Asset

The nature of combat injuries is shifting. A 15-year analysis of military casualties across multiple conflicts found that severe burns now account for a significantly larger share of combat wounds than they did a generation ago, up 50% over the study period. Recently published real-world military data, covering nearly 5,000 documented combat casualties across active conflict zones, found that NexoBrid was clinically applicable in 71% of war-related injuries.

In mass casualty events, surgical capacity is the first bottleneck. Operating rooms fill up, surgical teams are overwhelmed, and patients who need eschar removal wait, which increases infection risk and worsens outcomes. NexoBrid bypasses that bottleneck entirely: it works at bedside, requires no operating room, and completes debridement in hours.

A Track Record With the U.S. Government

The U.S. government has recognized this for years. BARDA's investment in NexoBrid has grown steadily since 2015, with each contract cycle expanding in scope and value, culminating in April when Vericel Corporation, MediWound's exclusive North American distributor, was awarded a new ten-year BARDA contract valued at up to $197 million for NexoBrid procurement, stockpiling, development of a room-temperature-stable formulation, and clinical development of a blast trauma indication.

The contract includes initial procurement for the U.S. Strategic National Stockpile and a Vendor Managed Inventory system, plus optional funding for the design of a U.S.-based manufacturing facility. The structure of these government agreements, with multi-year base periods and options for expanded procurement, suggests that countermeasure support may represent a recurring, growing revenue stream rather than a one-time event.

What Comes Next

The HERA/ICF inclusion now opens a parallel pathway in Europe. NexoBrid fits squarely into HERA's framework: it addresses high-acuity injury types, reduces reliance on surgical infrastructure, and has already demonstrated relevance in military and mass-casualty settings. As geopolitical instability continues and governments shift toward preparing for large-scale emergencies, the importance of scalable, field-relevant medical solutions is growing.

It is worth being honest about what ICF membership does and does not deliver. It does not guarantee a stockpiling contract or a procurement order. What it does is place MediWound inside the room where European preparedness priorities get translated into industrial decisions, where stockpiling deals and joint procurement agreements originate. MediWound's expanded NexoBrid manufacturing facility recently came online with six times the previous capacity, which means the company is, for the first time, positioned to supply meaningful volumes if European governments decide to start stockpiling.

The U.S. government's commitment to NexoBrid has grown with each contract cycle, from an initial investment in 2015 to a new ten-year agreement valued at up to $197 million. Whether Europe follows the same path remains to be seen. But the door is now open in a way it was not before, and for those watching the medical countermeasure space, that positioning could matter.

Read this Next >> Pancreatic Cancer Data Is Creating Billions in Value - This Multi-Cancer Platform Could Be Next (NASDAQ: DRTS)

Recent News Highlights From MediWound (Nasdaq:MDWD)

MediWound to Report First Quarter 2026 Financial Results

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx^® Data at Leading Wound Care Conferences

MediWound Reports BARDA Contract Award to Vericel for NexoBrid^® Valued at up to $197 Million

MediWound Files Annual Report on Form 20-F

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from MediWound Ltd. (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.